Latest News-SENHWA BIOSCIENCES, INC. Mediaroom_Page

Senhwa's Silmitasertib Receives US FDA Fast Track Designation for the Treatment of Recurrent Sonic Hedgehog Driven Medulloblastoma

TAIPEI and SAN DIEGO, Aug. 18, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a dr...

2021-08-19 10:57 1552

Senhwa Completes Enrollment of a Phase 2 Investigator Initiated Trial of Silmitasertib as Novel Oral Drug for COVID-19

TAIPEI and SAN DIEGO, Aug. 16, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new dr...

2021-08-16 15:29 1650

Senhwa Signs Agreement with Taiwan's CDE for COVID-19 Program Guiding Development of Silmitasertib

TAIPEI and SAN DIEGO, Aug. 13, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug d...

2021-08-14 10:48 2863

Senhwa Announces IND Submission to India's CDSCO of a Phase II Clinical Study for Silmitasertib as a Potential COVID-19 Treatment

TAIPEI and SAN DIEGO, June 23, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinic...

2021-06-23 19:00 1446

Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for Patients with Severe COVID-19

TAIPEI and SAN DIEGO, Jan. 21, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinic...

2021-01-22 12:00 1777

Senhwa Biosciences Presents Positive Cholangiocarcinoma Data

TAIPEI and SAN DIEGO, Jan. 15, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinic...

2021-01-15 22:00 2801

Senhwa Biosciences Receives US FDA 'Study May Proceed' Letter to Treat BRCA2+ or PALB2+ Solid Tumors With CX-5461

TAIPEI and SAN DIEGO, Dec. 23. 2020 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinic...

2020-12-24 10:40 2874

Senhwa Biosciences's Positive Topline Cholangiocarcinoma Data Abstract Accepted by 2021 ASCO Gastrointestinal Cancers Symposium

TAIPEI and SAN DIEGO, Dec. 13, 2020 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinic...

2020-12-14 10:09 1543

Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for COVID-19

Highlights: * The first hospitalized patient with severe COVID-19, treated under an eIND was dis...

2020-12-03 22:17 2405

Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations

TAIPEI and SAN DIEGO, Nov. 25, 2020 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinic...

2020-11-26 10:34 1938

CARE GA Receives Study May Proceed Letter from US FDA to Initiate Phase II Clinical Trial of Senhwa's Silmitasertib in COVID-19 Patients

TAIPEI and SAN DIEGO, Nov. 6, 2020 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinica...

2020-11-06 22:00 3520

Senhwa Announces Multiple IND application submissions to U.S. FDA for Silmitasertib as a Potential Treatment for COVID-19

TAIPEI and SAN DIEGO, Nov. 2, 2020 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinica...

2020-11-02 22:00 1738

Coronavirus Breakthrough: Senhwa Reports First eIND Silmitasertib Treated Severe COVID-19 Patient - Discharged Following Five Days of Treatment

TAIPEI and SAN DIEGO, Sept. 11, 2020 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clini...

2020-09-12 08:34 3597

Senhwa Biosciences's Silmitasertib Receives Rare Pediatric Disease Designation from U.S. FDA for Treatment of Recurrent Sonic Hedgehog Medulloblastoma

TAIPEI and SAN DIEGO, July 7, 2020 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a cli...

2020-07-07 21:00 2698

Latest News